ep line consensu forecast revenu estim mid-point
full year guidanc rais top bottom line humira sale ahead forecast
acquisit remain track close
ep line estim consensu full year
guidanc rais vs prior last publish ep
estim also increas dividend
sale estim
consensu drug beat estim includ humira upsid
 ou full year guidanc approach ou cer
line estim imbruvica full year guidanc
vs androgel venclexta full year guidanc vs
lupron skyrizi full year guidanc vs
rinvoq kaletra combin
forecast product estim includ mavyret full year
guidanc vs creon duodopa ultane/sevoflouran synthroid
combin light sale guidanc rais cer vs prior
approxim cer fx impact unchang last publish
revenu estim review
gpm estim
estim sg estim oper margin
estim net interest/oth expens line
estim tax rate forecast share count
estim guidanc gpm updat vs prior
approach tax rate rate vs prior rate
line item guidanc unchang
rinvoq upadacitinib ph ii data acr allergan cacciator acquisit close
expect complet list event shown follow page
pleas see page report import disclosur
cowen compani
chg total good profit margin royalti profit profit gross gross profit oper foreign exchang gain expens incom expens incom share cowen
cowen compani
cowen compani
cowen compani
time frameev w/bmi phase interim data mmnavitoclaxphas ii date myelofibrosi ashrinvoq upadacitinib phase ii data acr met endpointsveliparibphas vela data non-sq nsclcvencelxta w/rhhbi phase top-lin data two studi aml late imbruvicaphas ii data cll ashregulatoryimbruvicafil label updat cll ecog rinvoq upadacitinib eu approv ra posit chmp oct ii data uciniti phase ii jak/btki phase ii data rainiti phase ii sleimbruvicaphas selen data r/r fl/mzlphase shine data mclimbruvica venclextaphas sympatico data r/r mclrinvoqphas data select- ph data select- posit top-lin oct ph asphas data atop dermat ii data atop dermatitisphas ii data hsphase iib data ucvenclexta imbruvicaphas data cllregulatoryelagolixu approv uterin fibroid upadacitinib regulatori file mid approv ra gazyva w/rhhbi eu approv unfit cll acquisitionclos cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
